返回 A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Attends OCC 2017

[2017-06-19] 

Shanghai, China – From May 25 to May 28, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") attended the 11th Oriental Congress of Cardiology ("OCC 2017") in Shanghai Expo Center and hosted a satellite meeting and a case contest. The OCC 2017 was hosted by Shanghai Medical Association and Chinese Society of Cardiology, focusing on the development and application of modern science in the field of cardiovascular diseases, while providing cardiologists a platform for academic exchange.
 
On May 27, MicroPort® hosted a satellite meeting – "The Rhythm of MicroPort®: the Latest Clinical Data of TARGET Series Studies," co-chaired by Professor Jinghua Liu of Beijing Anzhen Hospital of Capital Medical University, Professor Yin Liu of Tianjin Chest Hospital, Professor Zuyi Yuan of the First Affiliated Hospital of Xi'an Jiaotong University and Professor Xianxian Zhao of Changhai Hospital of the Second Military Medical University. During the satellite meeting, Professor Bo Xu of Fuwai Hospital of Chinese Academy of Medical Sciences released the three-month Optical Computerized Tomography ("OCT") data from the TARGET All Comer trial for Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"). TARGET All Comer is the first post-market randomized trial in 10 European countries for Firehawk®. The TARGET All Comer study started in December 2015 and completed its enrollment in October 2016. A total of 1,656 patients were enrolled, including pre-specified 50 in the OCT sub-study and 176 in a QCA sub-study (13-month follow-up). During the meeting, Professor Jinjie Dai of Shanghai Chest Hospital, Professor Huimin Liu of the Second Affiliated Hospital of Harbin Medical University, and Professor Kun Wang of Nanjing Drum Tower Hospital also shared some cases using Firehawk® to further demonstrate its excellent performance in clinical application, which was well received by experts in attendance.
 
During the OCC 2017, MicroPort® displayed coronary stents, balloons, accessories, Columbus™ 3D EP Navigation System (Columbus™) and other products in its booth, and meanwhile set up the VR experience center in MicroPort® booth which provided visitors a more vivid understanding in the innovative technology of Firehawk® and attracted a lot of attention from the attendees. Besides, electrophysiologists including Professor Feifan Ouyang of St. Georg Hospital in Germany, Professor Zulu Wang from the General Hospital of Shenyang Military, Professor Yunlong Xia of the First Affiliated Hospital of Dalian Medical University, Professor Zheng Zhang of the First Hospital of Lanzhou University, Professor Yuehui Yin of the Second Affiliated Hospital of Chongqing Medical University, and Professor Jinlin Zhang of Wuhan Asia Cardiovascular Disease Hospital also visited MicroProt® booth to experience the performance of Columbus™. They expressed their expectations on the future innovations of MicroPort® and other domestic medical device companies, so that more high-end medical devices could be developed to benefit Chinese patients suffering from cardiovascular diseases.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:MicroPort® OrthoRecon Project Listed in National Key R&D Plan
[Next]:ARBORES™ Kyphoplastic Balloon Catheter Receives CE Mark Approval